Cellectis S.A. (EPA:ALCLS)
4.035
+0.305 (8.18%)
Dec 22, 2025, 4:39 PM CET
Cellectis Revenue
Cellectis had revenue of $16.73M USD in the quarter ending June 30, 2025, with 107.48% growth. This brings the company's revenue in the last twelve months to $56.30M, up 332.15% year-over-year. In the year 2024, Cellectis had annual revenue of $41.51M with 5,397.35% growth.
Revenue (ttm)
$56.30M
Revenue Growth
+332.15%
P/S Ratio
3.83
Revenue / Employee
$253.59K
Employees
222
Market Cap
269.77M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.51M | 40.75M | 5,397.35% |
| Dec 31, 2023 | 755.00K | -18.42M | -96.06% |
| Dec 31, 2022 | 19.17M | -11.18M | -36.83% |
| Dec 31, 2021 | 30.35M | -20.71M | -40.56% |
| Dec 31, 2020 | 51.06M | 35.87M | 236.12% |
| Dec 31, 2019 | 15.19M | 2.46M | 19.32% |
| Dec 31, 2018 | 12.73M | -12.46M | -49.46% |
| Dec 31, 2017 | 25.19M | -19.62M | -43.79% |
| Dec 31, 2016 | 44.81M | -11.06M | -19.79% |
| Dec 31, 2015 | 55.86M | 29.70M | 113.49% |
| Dec 31, 2014 | 26.17M | 18.79M | 254.88% |
| Dec 31, 2013 | 7.37M | -5.40M | -42.26% |
| Dec 31, 2012 | 12.77M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
Cellectis News
- 4 days ago - Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This - Seeking Alpha
- 5 days ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 5 days ago - Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Benzinga
- 6 days ago - Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis - GlobeNewsWire
- 6 days ago - Cellectis (CLLS) Arbitration Outcome Adjusts License Agreement - GuruFocus
- 6 days ago - Cellectis Announces Arbitral Decision in Dispute with Servier - GlobeNewsWire
- 10 days ago - Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy' - Seeking Alpha
- 14 days ago - ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL - GlobeNewsWire